UnitedHealth Group's 88.4% Medical Care Ratio Is Repricing, Not Cost Relief — and It Doesn't Weaken the December Hike Case

The medical care ratio is medical costs divided by premium revenue, so it can improve in three ways: lower cost per member, higher price for the same coverage, or favorable development on claims already booked. UnitedHealth Group used all three during 2026, and all three flattered the ratio without touching the underlying cost trend.

The sequence matters more than the headline. At 88.4%, the third quarter is the highest medical care ratio of 2026 so far, not the low point, and management puts commercial medical cost trend above 11% for 2026 and still north of 11% for 2027. The better ratio also sits on a shrinking revenue base: UnitedHealthcare earned $2.8 billion on a 3.3% operating margin against $1.8 billion on 2.1% a year earlier, while consolidated revenue slipped 0.4%. That is a margin rebuild, not a deflationary impulse.

The dispersion is the evidence. Elevance Health improved 70 basis points on Medicare Advantage and Individual ACA performance. Centene held flat at 92.7% and still cut full-year guidance. Molina Healthcare got 30 basis points worse, with Medicaid at 93.0% against 92.0% a year earlier. If the national cost trend had genuinely broken, the books with the least pricing freedom would have improved too. The Medicaid book is where the pressure showed up, not where it faded.

Two different prices sit inside the inflation gauge the Fed targets. Medical services are priced off producer price indexes for hospitals and physicians — the cost side of the bill. Health insurance is priced off what insurers actually charge, and in the PCE that is measured as net premiums: premiums minus benefits paid. When a medical care ratio falls, benefits fall faster than premiums, so net premiums per enrollee rise and the measured price of health insurance rises with them. A better margin for the payer mechanically adds a touch to measured insurance inflation.

The provider-side number did not improve with the margin. Hospital services inflation reached 7.59% year over year in February 2026, a post-pandemic high, and PwC projects group commercial medical cost trend of 9% for 2027 — the highest in 17 years — with individual trend at 8.5%. No Surprises Act arbitration has become a structural cost adder: UnitedHealth Group said awards can approach 6% of total medical spend in some regions, and providers won 88% of those disputes.

UnitedHealth Group is closing that wedge on the utilization side: a 30% cut in prior authorizations is expected by the end of 2026, including 67% in pediatrics, and use of AI ambient listening tools and patient-scheduled appointments rose 27% year over year with management expecting a compounding effect into 2027. The cost base is being administered harder, not priced lower, and the same administration shows up as revenue pressure on providers.

There is a second-order effect that matters more for providers than for the Fed. When an insurer improves its ratio by repricing or denying claims, the money does not disappear — it moves to the provider's revenue line, or out of the insured system altogether. PwC found that 70% of health plans now rank AI-enabled tools that capture more provider revenue as a top-three source of medical inflation. The money moves from the payer to the provider's price, and then out of the covered pool.

When insurers retreat from a market, members do not disappear. Centene reported Marketplace membership of 3.40 million against 5.83 million a year earlier — partly reclassification as dual-eligible members moved into Medicare — and a total at-risk book of 25.7 million against 28.0 million. HCA Healthcare reported increased uninsured volume from patients losing exchange coverage and put a $400 million pre-tax hit on third-quarter earnings from that shift alone. The industry's margin repair lands on hospital balance sheets, and HCA Healthcare guided 2027 earnings to be generally consistent with 2026 while expecting $550 million to $650 million less Medicaid supplemental benefit.

This is where the healthcare print gets demoted to a footnote. The Fed's problem is services inflation that is not visibly slowing, and healthcare is one piece of it — the piece least likely to break before January. For 2027, CMS expects weighted Medicare Advantage premiums to fall more than 16%, from $14.37 to $12.00, insurers project Medicare Advantage enrollment dropping from 36.3 million to 34 million, and KFF counts 193 counties with no Medicare Advantage drug plan for general enrollment against 123 a year earlier. The healthcare disinflation of 2027 arrives by shrinking the insured pool, which pushes cost into the uninsured and Medicaid books, where it surfaces as hospital bad debt and state budget pressure rather than a clean disinflation print.

The multiple has compressed rather than expanded: enterprise value to trailing EBITDA is 14.8 times against 15.4 times at the end of 2025 and 18.6 times at the end of 2024, because earnings recovered faster than the price. Full-year adjusted earnings of at least $20.50 against $16.35 delivered in 2025 is a 25% recovery, and the market capitalization is still 22% below its end-2024 level. The problem is not the level. Investors pay a 20.0-times multiple on UnitedHealth Group's guidance floor against 14.6 times for Elevance Health, which owns the same margin recovery with a smaller valuation.

The margin repair at UnitedHealth Group is real money: $5.1 billion of operating cash flow in the quarter, 1.2 times net income, and a guidance range raised for the third time this year. But the three sources of that margin — 2026 repricing, $610 million of reserve development and administrative efficiency — are contract-year or one-off items, and the company's own medical cost trend above 11% says nothing underneath has changed. Meanwhile the industry's cost shock is migrating rather than fading: out of insurance prices, which the Fed can measure, and into provider prices and uncompensated care, which it cannot. For the December 8-9 meeting that argues for a hike rather than against one. The cost shock is migrating, not fading, and the equity implication is to own the margin recovery at the lower price.